Bioavailability and Bioequivalence

Bioavailability and bioequivalence describe how much of an administered drug reaches the systemic circulation, how fast it does so, and whether two products deliver that exposure comparably. Bioavailability quantifies the rate and extent of absorption into the blood relative to a reference, while bioequivalence is the formal judgement that two products are interchangeable because their bioavailability is sufficiently similar. Together they form the quantitative bridge between a dosage form and the drug exposure a patient actually experiences.

Definition

Bioavailability is the rate and extent to which the active ingredient of a drug product is absorbed and becomes available at the site of action, conventionally measured by systemic exposure; bioequivalence is the conclusion that the rate and extent of absorption of two products do not differ to a clinically meaningful degree.

Scope

This area orients the reader to the concepts that govern systemic drug exposure from a pharmaceutical-sciences standpoint: absolute and relative bioavailability, the design and statistical assessment of bioequivalence studies, the first-pass losses that reduce oral availability, and the way food can alter absorption. It frames these as reference topics in biopharmaceutics, not as prescribing or dosing guidance.

Sub-topics

• absolute bioavailability
• bioequivalence studies
• first pass metabolism
• food drug interactions
• relative bioavailability

Core questions

• How much of an administered dose reaches the systemic circulation, and how quickly?
• How is exposure summarised from a plasma concentration-time curve (AUC, Cmax, Tmax)?
• When can two drug products be considered interchangeable?
• Which physiological and formulation factors reduce or alter bioavailability?

Key concepts

• Rate and extent of absorption
• Area under the concentration-time curve (AUC)
• Peak concentration (Cmax) and time to peak (Tmax)
• Absolute vs relative bioavailability
• First-pass (presystemic) elimination
• Average bioequivalence and the two one-sided tests procedure
• Biopharmaceutics Classification System

Mechanisms

Systemic exposure after extravascular dosing is governed by the fraction of dose that is liberated from the formulation, dissolves, permeates the gut wall, and survives presystemic metabolism in the gut and liver. The plasma concentration-time profile integrates these processes; its area under the curve reflects the extent of absorption while peak concentration and time to peak reflect the rate. Comparing exposure to an intravenous reference gives absolute bioavailability, while comparing two extravascular products gives relative bioavailability. Bioequivalence assessment then asks, statistically, whether the exposure metrics of a test product fall within accepted limits of a reference, typically using log-transformed AUC and Cmax in a crossover design analysed with the two one-sided tests procedure.

Clinical relevance

Bioavailability and bioequivalence underpin why a generic product can be substituted for an innovator and why route of administration and food can change the response to the same dose. They are reference concepts for interpreting how exposure is generated and compared; they describe the science behind product interchangeability and labelling rather than offering individual dosing or substitution advice.

Evidence & guidelines

Regulatory frameworks for bioequivalence rest on a statistical equivalence logic in which the 90% confidence interval for the test-to-reference ratio of exposure must lie within predefined limits, an approach formalised by Schuirmann's two one-sided tests procedure. The Biopharmaceutics Classification System of Amidon and colleagues links solubility and permeability to expected absorption behaviour and underlies biowaiver thinking, and textbook treatments such as Rowland and Tozer codify the underlying pharmacokinetic measurement.

History

The quantitative study of bioavailability grew out of mid-twentieth-century pharmacokinetics, as plasma concentration measurement made it possible to compare absorption across formulations and routes. Reports of clinically important differences between nominally identical products drove the development of formal bioequivalence testing, and Schuirmann's 1987 articulation of the two one-sided tests procedure gave the field its dominant statistical method. The 1995 Biopharmaceutics Classification System later connected physicochemical properties to absorption and reshaped how bioavailability is anticipated and waived.

Key figures

• Gordon Amidon
• Donald Schuirmann
• Malcolm Rowland
• Thomas Tozer

Seminal works

• amidon-1995
• schuirmann-1987

Frequently asked questions

What is the difference between bioavailability and bioequivalence?

Bioavailability measures the rate and extent to which a drug reaches the systemic circulation; bioequivalence is the comparative conclusion that two products deliver bioavailability similar enough to be considered interchangeable.

Which measurements summarise bioavailability?

Extent of absorption is summarised by the area under the plasma concentration-time curve (AUC), while the rate is captured by the peak concentration (Cmax) and the time to reach it (Tmax).